Strides Pharma, a step-down wholly-owned subsidiary of the company in the US, has acquired four approved ANDAs for the US market from Nostrum Laboratories, USA.

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.

The cumulative market size for the acquired portfolio is ~$ 57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million.

Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products.